Gu Tao, Li Cai-Xia, Feng Yan, Wang Qian, Li Chun-Hai, Li Chuan-Fu
Department of Radiology, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan 250012, Shandong Province, China.
World J Gastroenterol. 2007 Apr 14;13(14):2113-7. doi: 10.3748/wjg.v13.i14.2113.
To study the effect of adenovirus (Ad)-p53 gene therapy on hepatocellular carcinoma (HCC) in a rabbit model.
VX2 tumor was grown in the liver of 24 rabbits. Animals were divided into four groups: group A receiving trans-arterial gene therapy (Ad-p53) only, group B receiving combined Ad-p53 therapy and trans-arterial embolization (lipiodol), group C receiving trans-arterial chemoembolization (lipiodol + mitomycin C), control group (D) receiving sodium chloride. Tumor volume (V1) was measured by using MRI (d 13). Interventional procedure was applied (d 14). Tumor volume (V2) was assessed by MRI (d 21) and the mean ratio (V2/V1) was calculated. After the second MRI, specimens of the liver were abstained and examined immunohistochemically using mutant-type p53 antibody. The positive expression was scored.
Compared with control group (chi= 3.14 +/- 0.64), therapeutic groups all showed a significant decrease in the tumor growth ratio (P<0.05). A slight difference was found between group A (chi = 2.35 +/- 0.59) and group B (chi = 1.75 +/- 0.28) (P=0.048). No statistically significant difference was observed between group B and group C (chi = 2.00 +/- 0.44). The positive expression rate of mutant-type p53 was the lowest in group B and significantly different between group A and group C (P<0.05). Compared to the control subjects, groups A and C both showed a decrease in the expression of mutant-type p53, but there was no significant difference between them.
Trans-arterial Ad-p53 gene therapy can reduce tumor growth of HCC in rabbit model.
研究腺病毒（Ad）-p53基因治疗对兔肝细胞癌（HCC）模型的影响。
将VX2肿瘤种植于24只兔的肝脏。动物分为四组：A组仅接受经动脉基因治疗（Ad-p53），B组接受Ad-p53联合经动脉栓塞（碘油）治疗，C组接受经动脉化疗栓塞（碘油+丝裂霉素C），对照组（D组）接受氯化钠。使用MRI（第13天）测量肿瘤体积（V1）。在第14天进行介入操作。通过MRI（第21天）评估肿瘤体积（V2）并计算平均比值（V2/V1）。第二次MRI检查后，获取肝脏标本，使用突变型p53抗体进行免疫组织化学检查。对阳性表达进行评分。
与对照组（χ=3.14±0.64）相比，各治疗组肿瘤生长率均显著降低（P<0.05）。A组（χ=2.35±0.59）和B组（χ=1.75±0.28）之间存在轻微差异（P=0.048）。B组和C组之间未观察到统计学显著差异（χ=2.00±0.44）。突变型p53的阳性表达率在B组最低，A组和C组之间差异显著（P<0.05）。与对照组相比，A组和C组突变型p53的表达均降低，但两组之间无显著差异。
经动脉Ad-p53基因治疗可降低兔肝细胞癌模型中的肿瘤生长。
